GSK Seeks Approval for Lapatinib for Breast Cancer Patients in Japan
This article was originally published in PharmAsia News
Executive Summary
SpiritIndia.com (04/02/07)
|
SpiritIndia.com (04/02/07) GlaxoSmithKline has submitted a new treatment for Lapatinib to Japanese authorities as a treatment for advanced and metastatic HER2 positive breast cancer for women who already have received some therapy, including an anthracycline, a taxane, and trastuzumab. The approval application is seeking both monotherapy approval and approval for Lapatinib in combination with capecitabine. Lapatinib inhibits the tyrosine kinase aspects of EGFR and HER2 receptors. This then should decrease the cell proliferation that fuels tumor progression. On March 13, U.S. authorities approved capecitabine and Lapatinib as a combination therapy for this same condition. (Click here for more ) |